Ainos, Inc.

AIMD
About the company

Ainos, Inc., a dual-platform company, focusing artificial intelligence–based smelltech technologies and immune therapeutics. It offers AI Nose, an AI-based electronic olfaction system, which uses a smell language model to digitize scent into Smell IDs and turning into machine-readable data. The company provides its platforms for semiconductor manufacturing, robotics, and smart manufacturing industries; as well as senior care and women's health sectors.

Country: United StatesPrice: $1.23Market Cap: $10.7M

Investment snapshot

6%positive consensus
Scored 1d ago

Positive

1

BUY / PASS

Neutral / negative

1 / 14

NEUTRAL / FAIL

Median fair value

—

No comparable estimates

Models with upside

0 / 17

Positive margin of safety

Key risk

No clean pass — all 13 investors flag at least one valuation criterion

Framework analysis

VerdictMeaning
BUYPositive purchase signal: the framework's buy requirements are met.
PASSThe company clears the framework's checklist or screen, but the framework does not produce a buy signal. For valuation frameworks this often means margin of safety is missing, insufficient, or unavailable; some screen-only frameworks have no intrinsic-value BUY state.
NEUTRALNeither a positive nor negative conclusion. It does not mean to hold an existing position.
FAILThe company does not clear the framework's requirements.
RankedRanked strategies do not use PASS: selected cohort is BUY, outside the cohort is FAIL, and unranked is NEUTRAL.

Current investor scores use trailing 12-month flows and the latest balance sheet where supported. Multi-year and EPS tests retain annual history; each framework shows its financial basis below. Intrinsic values use annual financials.

MetricGraham

Defensive Value

Buffett

Quality Compounder

Lynch

GARP

Greenblatt

Magic Formula

Piotroski

F-Score

Dreman

Contrarian Value

Munger

Quality Focus

Pabrai

Dhandho Framework

Akre

Three-Legged Stool

Marks

Risk-Aware Value

Ackman

Activist Value

Templeton

Global Bargain Hunter

Sleep

Scale Economies Shared

Asness

Systematic Factors

Neff

Low-P/E Total Return

Schloss

Asset-Value Discipline

O'Shaughnessy

Systematic Factor Composite

VerdictFAILFAILFAILNot rankedPASSFAILFAILFAILFAILFAILFAILFAILFAILFAILFAILFAILNEUTRAL
Score
AnalysisChecking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…
Intrinsic Value (annual)N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Margin of SafetyN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Financial Basis

TTM ended 2026-06-30 · Balance sheet at 2026-06-30 · Annual history · FY 2025

Latest source filing: 2026-08-03

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-06-30

Latest source filing: 2026-08-03

Score computed: 2026-11-14

Annual history · FY 2025 · Balance sheet at 2026-06-30 · TTM ended 2026-06-30 vs 2025-06-30 · TTM ended 2026-06-30

Latest source filing: 2026-08-03

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-03-30

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-03-30

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-06-30 · Balance sheet at 2026-06-30 · Market data at 2026-11-01

Latest source filing: 2026-08-03

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025 · TTM ended 2026-06-30 · Balance sheet at 2026-06-30

Latest source filing: 2026-08-03

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025

Latest source filing: 2026-03-30

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment · Balance sheet at 2026-06-30

Latest source filing: 2026-08-03

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-06-30 · Qualitative assessment

Latest source filing: 2026-08-03

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-06-30 · Balance sheet at 2026-06-30 · Market data at 2026-11-01

Latest source filing: 2026-08-03

Score computed: 2026-11-14

Annual history · FY 2025 · Price history 2025-01-01–2026-11-01 · Balance sheet at 2026-06-30

Latest source filing: 2026-08-03

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2026-03-30

Score computed: 2026-11-14

TTM ended 2026-06-30 · Balance sheet at 2026-06-30 · Price history 2025-01-01–2026-11-01 · Annual history · FY 2025

Latest source filing: 2026-08-03

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-03-30

Score computed: 2026-11-14

Annual history · FY 2025 · Balance sheet at 2026-06-30

Latest source filing: 2026-08-03

Score computed: 2026-11-14

TTM ended 2026-06-30 · Annual history · FY 2025 · Price history 2025-01-01–2026-11-01

Latest source filing: 2026-08-03

Score computed: 2026-11-14

Where It Passes

    Where It Falls Short

    • Valuation0% pass✓ 4✗ 24▾

      No clean pass — all 13 investors flag at least one valuation criterion

      Price / Book Value per Share1.0x
      ✓Dreman< 1.2x✓Templeton< 1.5x✗SchlossP/B <= 0.80x (app cutoff)
      Price / 3-yr avg EPS
      ✗Graham<= 15x
      Price-to-Book Ratio1.0x
      ✓Graham<= 1.5x
      P/E x P/B
      ✗Graham<= 22.5
      Basic earnings-growth PEG (dividends excluded)
      ✗Lynch< 1.0 (ideally < 0.5)
      EBIT / Enterprise Value-65.7%
      ✗Greenblatt> 10%
      Earnings Yield + ROC AssessmentEY=-65.7%, ROC=N/A (invested capital <= 0)
      ✗GreenblattBoth EY > 10% and ROC > 25%
      Price / EPS
      ✗Dreman< 12x✗Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)
      Price / (CFO / Shares)N/A (negative CFPS)
      ✗Dreman< 8x
      Valuation ReasonablenessOE Yield=-138.6%
      ✗MungerP/E < 25 or Owner Earnings Yield > 5%
      P/E or FCF YieldFCF Yield=-43.4%
      ✗PabraiP/E < 15 or FCF Yield > 10%
      P/B or P/E vs. Historical AverageP/B=1.0x
      ✓MarksP/E < 15 or P/B < 2.0
      Discount to Intrinsic ValueN/A (negative normalized EPS)
      ✗Marks>= 20% below intrinsic value
      Price / FCF per ShareN/A (negative FCF)
      ✗Ackman<= 25
      Price vs. Trailing Low196% of trailing low ($0.63)
      ✗Templeton<= 120% of trailing low (certified split-adjusted live window)
      Net income / market capitalization-134.81%; #5530/6340 (top 87.2%)
      ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
      Positive book equity / market capitalization+0.3063; #3674/6449 (top 57.0%)
      ✗AsnessTop 30% of eligible cross-section
      Price / Diluted EPS
      ✗NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)
      (EPS CAGR % + Dividend Yield %) / P/E
      ✗Neff> 0.7 (Neff's published traditional edge)
      Price / Tangible Book Value per ShareN/A (non-positive TBVPS)
      ✗SchlossP/TBV <= 1.00x (app cutoff)
      Book Value per Share Change
      ✗SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)
      Revenue / market capitalization+0.0013; #5010/5247 (top 95.5%)
      ✗OshaughnessyTop 10% of eligible cross-section
      (Operating cash flow - capex) / market capitalization-43.36%; #3805/4519 (top 84.2%)
      ✗OshaughnessyTop 10% of eligible cross-section
      Trailing six-month price return through the evaluation date-48.32%; #5096/6202 (top 82.2%)
      ✗OshaughnessyTop 10% of eligible cross-section
    • Cash Flow0% pass✓ 1✗ 11▾

      No clean pass — all 10 investors flag at least one cash flow criterion

      Free Cash Flow Proxy$-10.0M
      ✗BuffettPositive and growing
      FCF Positive and Growing$-4.6M
      ✗LynchPositive and growing
      Operating Cash Flow$-4.6M
      ✗PiotroskiCFO > 0
      (CFO / Total Assets) vs ROACFO/Assets=-22.11%, ROA=-70.77%
      ✓PiotroskiCFO/Assets > ROA
      Price / (CFO / Shares)N/A (negative CFPS)
      ✗Dreman< 8x
      P/E or FCF YieldFCF Yield=-43.4%
      ✗PabraiP/E < 15 or FCF Yield > 10%
      FCF Positive0/10 years FCF positive
      ✗MarksPositive FCF in majority of recent years
      (OCF - CapEx) / Market Cap-64.3%
      ✗Ackman>= 4%
      Price / FCF per ShareN/A (negative FCF)
      ✗Ackman<= 25
      Positive Operating Cash Flow frequency0/15 years positive
      ✗SleepPositive OCF in >= 70% of available years
      Operating Cash Flow - Capital Expenditures$-4.6M
      ✗Neff> $0 (app proxy for a strong fundamental case)
      (Operating cash flow - capex) / market capitalization-43.36%; #3805/4519 (top 84.2%)
      ✗OshaughnessyTop 10% of eligible cross-section
    • Growth0% pass✓ 1✗ 12▾

      No clean pass — all 8 investors flag at least one growth criterion

      EPS Growth (3-yr avg, 10-yr window)-28033.3%
      ✗Graham>= 33% growth
      Basic earnings-growth PEG (dividends excluded)
      ✗Lynch< 1.0 (ideally < 0.5)
      3-5 Year EPS CAGR
      ✗Lynch15-30% (Fast Grower); > 0% to pass
      Inventory Growth vs Revenue GrowthInv: 92.9% vs Rev: -87.7%
      ✗LynchInventory growth < Revenue growth
      EPS Growth Direction$0.01 (2010) -> $-3.46 (2025)
      ✗DremanPositive over recent years
      EPS CAGR
      ✗Dreman> 5% annualized
      Positive Net Income Frequency1/15 years positive
      ✗MarksPositive net income in >= 7 of last 10 years
      3yr Median Revenue Growth-83.0%
      ✗Ackman>= 5%
      Positive EPS Growth Frequency2/3 years with positive EPS growth
      ✗AckmanPositive EPS growth in >= 3 of last 5 years
      5-Year EPS CAGR
      ✗Templeton> 0% (5-year EPS CAGR)
      Revenue growth vs. gross and operating margin trendgross margin -207.8% -> 82.9%, operating margin -10815.0% -> -11268.3%
      ✗SleepRevenue rising; gross margin flat or falling; operating margin holding
      5-year Revenue CAGR49.6%
      ✓SleepCAGR > 7%
      3-5 Year Diluted EPS CAGR
      ✗Neff7%-20% annualized
    • Efficiency0% pass✓ 1✗ 10▾

      No clean pass — all 8 investors flag at least one efficiency criterion

      Current Ratio0.13
      ✗Graham>= 2.0
      ROIC (3-5 yr avg)-42.4%
      ✗Buffett> 10%
      ROIC - WACC-52.4%
      ✗BuffettPositive (WACC = 10%)
      EBIT / (NWC + Net Fixed Assets)N/A (invested capital <= 0)
      ✗Greenblatt> 25%
      Current Ratio Change YoY1.10 -> 1.06
      ✗PiotroskiIncreased YoY
      Revenue / Total Assets Change YoY0.00x -> 0.01x
      ✓PiotroskiImproved YoY
      Current Assets / Current Liabilities0.13
      ✗Dreman> 1.5
      Return on Invested Capital-76.1%
      ✗Munger> 15%
      ROIC (high and growing)FY2023: ROIC=-34.3%; FY2024: ROIC=-39.7%; FY2025: ROIC=-59.5%
      ✗AkreLatest 3 consecutive FYs: ROIC > 15% in each
      Reinvestment Rate x ROICN/A (non-positive net income)
      ✗AkreReinvestment Rate * ROIC > 10%
      ROIC (5-year)0/5 years above 12% (latest -59.5%)
      ✗SleepROIC > 12% in a majority of years
    • Profitability6% pass✓ 4✗ 31▾

      15 of 16 flag AIMD's profitability — Graham, Buffett, Lynch +12 more

      Positive EPS (10 years)1/18 years positive
      ✗GrahamPositive EPS every year for 10 years
      EPS Growth (3-yr avg, 10-yr window)-28033.3%
      ✗Graham>= 33% growth
      Net Income Positive (10+ years)1/18 years positive
      ✗BuffettPositive every year for 10+ years
      ROE (up to 5-year arithmetic mean)-85.2%
      ✗Buffett> 15% arithmetic mean (app rule)
      Operating Margin (10-yr trend)-11268.3% (latest)
      ✓BuffettStable or rising over 10 years
      Free Cash Flow Proxy$-10.0M
      ✗BuffettPositive and growing
      Earnings Variance (10-yr CoV)N/A (negative mean EPS)
      ✗BuffettCoV < 0.3
      Retained Earnings Effectiveness
      ✗Buffett$1 retained -> > $1 market value created
      Basic earnings-growth PEG (dividends excluded)
      ✗Lynch< 1.0 (ideally < 0.5)
      3-5 Year EPS CAGR
      ✗Lynch15-30% (Fast Grower); > 0% to pass
      ROE-440.2%
      ✗Lynch> 15%
      EBIT / Enterprise Value-65.7%
      ✗Greenblatt> 10%
      Earnings Yield + ROC AssessmentEY=-65.7%, ROC=N/A (invested capital <= 0)
      ✗GreenblattBoth EY > 10% and ROC > 25%
      Net Income / Total Assets-70.77%
      ✗PiotroskiROA > 0
      ROA Change YoY-51.57% -> -70.77% (delta: -19.20%)
      ✗PiotroskiCurrent ROA > Prior ROA
      (CFO / Total Assets) vs ROACFO/Assets=-22.11%, ROA=-70.77%
      ✓PiotroskiCFO/Assets > ROA
      Gross Margin Change YoY-153.7% -> 82.9%
      ✓PiotroskiImproved YoY
      Pre-Tax Income / Revenue-106277.4%
      ✗Dreman>= 8%
      Net Income / Shareholders' Equity-440.2%
      ✗Dreman> 12%
      Margin of SafetyP/B=1.0x
      ✓PabraiP/B < 1.5 or P/E < 15
      Return on Equity-115.8% (3-yr avg)
      ✗AkreROE > 20% (3-year avg)
      Discount to Intrinsic ValueN/A (negative normalized EPS)
      ✗Marks>= 20% below intrinsic value
      Positive Net Income Frequency1/15 years positive
      ✗MarksPositive net income in >= 7 of last 10 years
      Operating Income / Revenue-101210.2%
      ✗Ackman>= 15%
      Net Income / Shareholders Equity-440.2%
      ✗Ackman>= 15%
      5-Year EPS CAGR
      ✗Templeton> 0% (5-year EPS CAGR)
      Operating Margin Trend-10815.0% (2023) -> -11268.3% (2025)
      ✗TempletonNon-negative operating-margin trend over 3 years
      Revenue growth vs. gross and operating margin trendgross margin -207.8% -> 82.9%, operating margin -10815.0% -> -11268.3%
      ✗SleepRevenue rising; gross margin flat or falling; operating margin holding
      Net income / market capitalization-134.81%; #5530/6340 (top 87.2%)
      ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
      Gross profit / total assets+0.05%; #3457/3702 (top 93.4%)
      ✗AsnessTop 30% of eligible cross-section
      Net income / positive book equity-440.15%; #5052/5226 (top 96.7%)
      ✗AsnessTop 30% of eligible cross-section
      Negative 5-year standard deviation of ROA-0.1996; #4235/5884 (top 72.0%)
      ✗AsnessTop 30% of eligible cross-section
      3-5 Year Diluted EPS CAGR
      ✗Neff7%-20% annualized
      Positive Diluted-EPS Years0/9 years positive
      ✗Schloss>= 70% positive over 5-10 observed years (app rule)
    • Verdicts7% pass✓ 1✗ 14▾

      Split decision: 14 FAIL · 1 PASS · 1 NEUTRAL

      Overall verdict
      ✗GrahamFAIL (1/9)✗BuffettFAIL (1/9)✗LynchFAIL (0/7)•GreenblattNot ranked✓PiotroskiPASS (F-Score 5)✗DremanFAIL (1/11)✗MungerFAIL (1/4)✗PabraiFAIL (1/3)✗AkreFAIL (0/6)✗MarksFAIL (1/5)✗AckmanFAIL (1/9)✗TempletonFAIL (2/8)✗SleepFAIL (1/6)✗AsnessFAIL (Rank #2363/2370 (Top 99.7%))✗NeffFAIL (1/6)✗SchlossFAIL (0/7)•OshaughnessyNEUTRAL (Not ranked)
    • Debt & Leverage8% pass✓ 1✗ 14▾

      11 of 12 flag AIMD's debt & leverage — Graham, Buffett, Lynch +8 more

      LT Debt vs Net Current Assets
      ✗GrahamLT Debt <= Net Current Assets
      Debt/Equity & Interest CoverageD/E: 3.35, IC: -18.8x
      ✗BuffettD/E < 0.5 AND Interest Coverage > 5x
      Total Debt / Equity3.35
      ✗Lynch< 0.33
      Cash - Long-term Debt
      ✗LynchPositive preferred
      LT Debt / Total Assets Change0.00% -> 0.00%
      ✓PiotroskiDecreased YoY
      Current Assets / Current Liabilities0.13
      ✗Dreman> 1.5✗SchlossCurrent ratio >= 1.50x (app cutoff)
      Total Debt / Shareholders' Equity3.35
      ✗Dreman< 0.8✗Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✗SchlossD/E < 1.00x
      Debt Levels3.35
      ✗MungerDebt/Equity < 0.5✗AkreDebt/Equity < 0.3
      Interest Coverage & Debt/EBITDAIC=-18.8x, D/EBITDA=N/A
      ✗MarksInterest Coverage > 3x; Debt/EBITDA < 4x
      Total Debt / Shareholders Equity3.35
      ✗Ackman<= 1.0
      Negative debt-to-equity (higher means less debt)-3.3496; #3962/4210 (top 94.1%)
      ✗AsnessTop 30% of eligible cross-section

    Business & financials

    Financial snapshot: annual FY 2025. Current investor scores may use newer quarterly data.

    Company Profile

    Industry: Pharmaceutical Products
    SIC Sector: Chemicals & Pharmaceuticals
    Size: Micro Cap($10.7M)
    Revenue: $124157.00+499.0% YoY
    Net Income: $14.8M+0.6% YoY

    Financial Snapshot

    Operating Margin-11268.3%
    Return on Equity-195.3%
    Debt / Equity1.45
    Current Ratio1.06
    EPS (Diluted)$-3.46
    Shares Retired−90.7% / −25.8% 2y

    Shareholder Return

    Fiscal 2025

    Issued 90.7% of shares last year, 25.8% issued over two.

    Buybacks
    —
    Dividends
    —

    Company Financials

    Latest TTM and quarters alongside annual years

    TTM sums four consecutive quarters and uses the latest quarter-end balances. Quarter columns show three-month results; annual columns show full-year totals. Growth compares the same period a year earlier. EPS is not added for TTM; full-year ratios are blank for quarters.

    The latest annual period end is unavailable. Showing the latest fiscal cycle’s quarters; quarter and annual columns may overlap. Quarterly shows the full quarter history.

    MetricTTM · 2026-06-30

    2025-07-01 – 2026-06-30

    Sources · derived quarter values

    Derived from cumulative filings: operating cash flow, depreciation amortization, capex, revenue, net income, operating income, gross profit, ebit, pre tax income, interest expense.

    Q2 FY 2026

    2026-04-01 – 2026-06-30

    Sources · derived quarter values

    Derived from cumulative filings: operating cash flow, depreciation amortization, capex.

    Q1 FY 2026

    2026-01-01 – 2026-03-31

    Sources
    FY 2025
    Sources
    • 10-K · 2026-03-30
    FY 2024
    Sources
    • 10-K · 2025-03-07
    FY 2023
    Sources
    • 10-K · 2024-03-08
    FY 2022
    Sources
    • 10-K · 2023-04-03
    FY 2021
    Sources
    • 10-K · 2022-03-21
    Market Cap$10.7Mcurrent----$11.8Mest.$10.5Mest.$22.2Mest.$395.2Mest.$33.0Best.
    Revenue$13.6K↓88%$152↓97%$161↓100%$124.2K↑499%$20.7K↓83%$122.1K↓97%$3.5M↑492%$594.6K
    Operating Income-$13.8M↑6%-$4.4M↓17%-$2.3M↑28%-$14.0M↓1%-$13.8M↓5%-$13.2M↑6%-$14.0M↓261%-$3.9M
    Net Income-$14.5M↑8%-$4.6M↓12%-$2.5M↑25%-$14.8M↑1%-$14.9M↓8%-$13.8M↑2%-$14.0M↓260%-$3.9M
    EPS (Diluted)--$-0.62↑37%$-0.41↓95%$-3.46↓122%$-1.56↑54%$-3.36--$-0.03
    Gross Margin78.7%↓4%65.1%↓18%-373.9%↓551%82.9%↑154%-153.7%↑26%-207.8%↓620%39.9%↓42%69.0%
    Operating Margin-101210.2%↓670%-2894135.5%↓3503%-1418414.3%↓47529%-11268.3%↑83%-66772.2%↓517%-10815.0%↓2624%-397.1%↑39%-650.5%
    ROE-440.2%↓220%——-195.3%↓104%-95.8%↓70%-56.3%↓39%-40.4%↓6%-38.1%
    Total Debt$11.0M$11.0M$11.0M↓8%$11.0M↓8%$12.0M↑101%$6.0M↑575%$884.0K↑314%$213.4K
    Shareholders' Equity$3.3M↓71%$3.3M↓71%$5.7M↓57%$7.6M↓51%$15.5M↓37%$24.4M↓29%$34.6M↑240%$10.2M
    Current Ratio0.13↓95%0.13↓95%0.55↓72%1.06↓4%1.10↓41%1.85↑61%1.15↑1488%0.07
    Debt / Equity3.35↑248%3.35↑248%1.93↑111%1.45↑88%0.77↑217%0.24↑856%0.03↑22%0.02
    Operating Cash Flow-$4.5M↑9%-$1.4M↓7%-$983.4K↑20%-$4.6M↑21%-$5.8M↓24%-$4.7M↓54%-$3.0M↓143%-$1.2M
    Free Cash Flow---$1.5M-$992.0K↑21%-$4.6M↑20%-$5.8M↓22%-$4.8M↓30%-$3.7M↓164%-$1.4M

    Score history

    Historical Score Timeline

    Industry peers

    Industry Peers

    Similar companies in Pharmaceutical Products

    AIMD vs Peers — Financial Grading

    Revenue$124157.00Bottom 25%
    Net Income$14.8MBottom 25%
    ROE-195.3%Bottom 25%
    D/E1.45Median
    Op. Margin-11268.3%Bottom 25%
    Curr. Ratio1.06Bottom 25%
    CompanyMarket CapPriceRevenueNet IncomeROED/EOp. MarginCurr. RatioGrahamBuffettLynchGreenblattPiotroskiDreman
    Merck & Co., Inc.MRK$364.3B$147.76$65.0B$18.3B34.7%0.94—1.542/95/94/70/3F-Score 41/11
    ABBOTT LABORATORIESABT$188.0B$108.52$44.3B$6.5B12.5%0.2518.2%1.583/94/92/71/3F-Score 53/11
    BRISTOL MYERS SQUIBB COBMY$129.7B$63.43$48.2B$7.1B38.2%2.4419.4%1.262/91/93/71/3F-Score 85/11
    BIO-TECHNE CorpTECH$11.4B$72.80$1.2B$73.4M3.8%—8.4%3.464/93/93/70/3F-Score 54/11
    REPLIGEN CORPRGEN$10.7B$167.79$738.3M$48.9M2.3%0.267.5%8.373/92/93/70/3F-Score 75/11
    IONIS PHARMACEUTICALS INCIONS$4.8B$29.06$943.7M$381.4M-78.0%3.60-40.4%3.833/91/91/70/3F-Score 43/11
    NEOGEN CORPNEOG$2.5B$11.23$870.4M$7.9M-0.4%0.76-2.5%3.823/91/92/70/3F-Score 64/11
    Pharvaris N.V.PHVS$2.4B$33.36—$206.4M-64.8%0.00——0/90/92/70/3F-Score 22/11